abbv-321
mAbexperimentalADC
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 10, 2017 (NCT03234712)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
EGFR inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- pyrrolobenzodiazepine
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03234712 | Phase 1 | Oct 10, 2017 | AbbVie |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 1 | 1 | 1 | 2017 |
1 organizations
Page 1 / 1